Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 3, 2015, Pages 539-543

  Nieves, Diana ^a   Puig Peiró, Ruth ^b   Ferrándiz, Carlos ^c   Plazas, Maria Josep ^d   Brosa, Max ^a  

^a Oblikue Consulting   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Medical Department of Spain ^*  (Spain)

Author keywords

5 fluorouracil salicylic acid; actinic keratosis; costeffectiveness analysis; cryotherapy; Spain

Indexed keywords

DERMATOLOGICAL AGENT; FLUOROURACIL PLUS SALICYLIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; FLUOROURACIL; KERATOLYTIC AGENT; SALICYLIC ACID;

ACTINIC KERATOSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; HEALTH CARE COST; HUMAN; QUALITY ADJUSTED LIFE YEAR; REVIEW; SPAIN; TREATMENT OUTCOME; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COMBINATION; ECONOMICS; KERATOSIS, ACTINIC; PROCEDURES;

ANTIMETABOLITES, ANTINEOPLASTIC; COST-BENEFIT ANALYSIS; CRYOTHERAPY; DECISION SUPPORT TECHNIQUES; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; KERATOLYTIC AGENTS; KERATOSIS, ACTINIC; QUALITY-ADJUSTED LIFE YEARS; SALICYLIC ACID; SPAIN;

EID: 84929255268     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.995171     Document Type: Review

References (23)

1. Holmes C, Foley P, Freeman M, Chong AH. Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas J Dermatol 2007;48:67-74
2. de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-30.
3. Erratum in: Br J Dermatol 2008;158:873
4. Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology 2008;216:194-9
5. Massa A, Alves R, Amado J, et al. [Prevalence of cutaneous lesions in Freixo de Espada a Cinta]. Acta Med Port 2000;13:247-54
6. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;142:1154-9
7. Naldi L, Chatenoud L, Piccitto R, et al. Prevalence of actinic keratosis and associated factors in a representative sample of the Italian adult population: results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. Arch Dermatol 2006;142:722-6
8. Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol 2013; 68(Suppl 1):S20-7
9. Ferrándiz C, Fonseca-Capdevila E, García-Diez A, et al. Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis. Actas Dermosifiliogr 2014;105:378-93
10. Berman B, Amini S. Pharmacotherapy of actinic keratosis: an update. Expert Opin Pharmacother 2012;13:1847-71
11. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003;139:66-70
12. General Spanish Council of Pharmacist. Madrid. Spain, 2014. Available from: www. portalfarma.com [Last accessed 1 March 2014]
13. Dirschka T, Dominicus R, Lars K, et al. Long term efficacy and recurrence of topical 0.5% 5-fluorouracil with 10% salicylic acid for actinic keratosis compared to cryotherapy a prospective, active controlled, randomized, exploratory study [Poster]. In: 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres and 8th EADO Congress. Barcelona. Spain, 2012. Available from: www.eado.org/activities/ eado-congress/8 [Last accessed 1 March 2014]
14. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011;165: 1101-8
15. Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 2010;28:1055-64
16. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62
17. Spanish Health Costs Database eSalud. Oblikue Consulting S.L. Barcelona. Spain, 2014. Available at www.oblikue.com [Last accessed 7 july 2014]
18. Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol 2012;22: 370-4
19. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl 2):34-40
20. Czarnecki D, Meehan CJ, Bruce F, Culjak G. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 2002;6:207-9
21. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115: 2523-30
22. Colombo GL, Chimenti S, Di Matteo S, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol 2010;145:573-81
23. Fluorouracil 0.5%/ salicylic acid 10% cutaneous solution (Actikerall). SMC No. (728/11). Scottish Medicines Consortium (SMC). 2011. Available from: http://www. scottishmedicines.org.uk/files/advice/ fluorouracil-and-salicylic acid-Actikerall-FINAL-September-2011-for-website.pdf [Last accessed 1 March 2014]